Gilead Sciences News
News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.
Trending on the Topix Network
Join us at the The Encore Las Vegas in Las Vegas, NV, where we will bring together the top student housing executives from across the country who will cover the hottest topics in financing, investment, brokerage, development and property management, our industry leaders will give the highest level views on the sector - at RealShare STUDENT HOUSING ... (more)
2... )--Gilead Sciences, Inc. announced today that its first quarter 2014 financial results will be released on Tuesday, April 22, at 4:05 p.m. Eastern ... )--Diodes Incorporated , a leading global manufacturer and supplier of high-quality application specific standard products within the broad discrete, logic... )--Q2 Holdings, Inc. announced ... (more)
At 4:15 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the first quarter 2014 and provide a general business update.
Activist investor Daniel Loeb, who is fighting to win control of three board seats at Sotheby's , on Monday raised the temperature by saying the current board has failed and that its attacks on him are "false" and "misleading."
Antiviral products generate about 86% of the total revenues, and the product group is also vitally important for the company's top and bottom line growth.
Bloomberg reports that pharmacy benefits manager Express Scripts, which handles drug reimbursement for a big chunk of the U.S. private insurance market, says it's forming a coalition to refuse to use Sovaldi after a competitor hits the market.
Orlando Chavez, who works at the Berkeley Free Clinic, was cured of hepatitis C in 2005 after painful treatment and says he would have jumped on Gilead's new drug, Sovaldi, at any price.
The health and biomedical industries in Silicon Valley saw a 15.5 percent increase in profits in 2013 -- representing $4.4 billion -- but, perhaps more importantly, venture capital also began flowing after nearly five years of lean investments.
Developing countries are seeking to pay as little as 1 percent of the $84,000 price Gilead Sciences Inc. is charging U.S. patients for its new hepatitis C drug.
In trading on Friday, the Biotech ETF is outperforming other ETFs, up about 0.4% on the day.
The bump follows a Reuters report that the Texas Health and Human Services Commission will reconsider its restrictive recommendation to Medicaid concerning Gilead Science's hepatitis C drug treatment, Sovaldi, due to the drug's high costs.
The iShares Nasdaq Biotech ETF fell 5.6% to $221.89 today, while the SPDR S&P Biotechnology ETF dropped 6.5% to $129.79.
Gilead Sciences, Inc. today announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi 400 mg was administered for the treatment of chronic hepatitis C virus infection in patients with advanced liver disease.
Gilead anuncia resultados de Fase 2 de dos regmenes basados en sofosbuvir totalmente orales en fase de investigacin para el tratamiento de la hepatitis C crnica )--Gilead Sciences, Inc. ha anunciado los datos de dos estudios de Fase 2 que evaluan regimenes totalmente orales en fase de investigacion que contienen el inh... )--Law office of Brodsky & ... (more)